APOE and Alzheimer disease: In particular, long term ω-3 supplementation reportedly reduced AD risk by 71% in the ApoE ε4+ group but no significant reduction was found for ApoE ε4− participants while none of the blood biomarkers (ω-3, DHA, ALA) were significantly associated with AD risk, regardless of ApoE ε4 status.